SUZANNE L TOPALIAN
Medical Practice in Unity, MD
License number
Pennsylvania MD024628E
Category
Medicine
Type
Medical Physician and Surgeon
Address
Address
2
Unity, MD 20833
Pennsylvania
Pennsylvania
Personal information
See more information about SUZANNE L TOPALIAN at radaris.comName
Address
Phone
19400 James Creek Ct, Brookeville, MD 20833
Professional information
See more information about SUZANNE L TOPALIAN at trustoria.com
Mhc-Class Ii Restricted Melanoma Antigens And Their Use In Therapeutic Methods
Mhc-Class Ii Restricted Melanoma Antigens And Their Use In Therapeutic Methods
US Patent:
7501501, Mar 10, 2009
Filed:
Oct 8, 2004
Appl. No.:
10/962143
Inventors:
Suzanne L Topalian - Brookeville MD, US
Steven A Rosenberg - Potomac MD, US
Paul F Robbins - Silver Spring MD, US
Steven A Rosenberg - Potomac MD, US
Paul F Robbins - Silver Spring MD, US
Assignee:
The United States of America as represented by the Secretary Department of Health and Human Services - Bethesda MD
International Classification:
C07H 21/04
US Classification:
536 231, 536 235
Abstract:
The present invention provides MHC Class II restricted melanoma antigens recognized by CD4 T cells. This invention further provides prophylactic and therapeutic applications for the Class II restricted melanoma antigens. In particular, this invention provides tyrosinase Class II restricted melanoma antigens, as well as tyrosinase immunogenic peptides which have been modified to enhance their immunogenicity. These antigens can serve as an immunogens or vaccines to prevent or treat melanoma. In addition a method for isolating Class II restricted melanoma antigens or identifying new Class II restricted melanoma antigens is provided.
Melanoma Cell Lines Expressing Shared Immunodominant Melanoma Antigens And Methods Of Using Same
Melanoma Cell Lines Expressing Shared Immunodominant Melanoma Antigens And Methods Of Using Same
US Patent:
6187306, Feb 13, 2001
Filed:
Aug 5, 1997
Appl. No.:
8/906029
Inventors:
Drew M. Pardoll - Brookeville MD
Elizabeth Jaffee - Lutherville MD
Adam Adler - Pikesville MD
Suzanne L. Topalian - Brookeville MD
Steven A. Rosenberg - Potomac MD
Elizabeth Jaffee - Lutherville MD
Adam Adler - Pikesville MD
Suzanne L. Topalian - Brookeville MD
Steven A. Rosenberg - Potomac MD
Assignee:
The Johns Hopkins Universtiy - Baltimore MD
The United States of America as represented by the Department of Health and
Human Services - Washington DC
The United States of America as represented by the Department of Health and
Human Services - Washington DC
International Classification:
A61K 4800, C12N 1585
US Classification:
424 9321
Abstract:
The invention pertains to a method of treating or protecting against melanoma that comprises (a) obtaining a melanoma cell line that expresses one or more shared immunodominant melanoma antigens, (b) modifying the melanoma cell line to render it capable of producing an increased level of a cytokine relative to the unmodified cell line, and (c) administering the melanoma cell line to a mammalian host that has melanoma or is at risk for developing melanoma. Preferably the melanoma cell line is allogeneic and is not MHC-matched to the host.
Phosphopeptides As Melanoma Vaccines
Phosphopeptides As Melanoma Vaccines
US Patent:
2012017, Jul 12, 2012
Filed:
May 4, 2010
Appl. No.:
13/318821
Inventors:
Suzanne L. Topalian - Brookeville MD, US
Florence Depontieu - Lyon, FR
Donald Hunt - Charlottesville VA, US
Jeffrey Shabanowitz - Charlottesville VA, US
Jie Qian - Bridgewater NJ, US
Victor Engelhard - Crozet VA, US
Angela Zaring - charlottesviille VA, US
Florence Depontieu - Lyon, FR
Donald Hunt - Charlottesville VA, US
Jeffrey Shabanowitz - Charlottesville VA, US
Jie Qian - Bridgewater NJ, US
Victor Engelhard - Crozet VA, US
Angela Zaring - charlottesviille VA, US
Assignee:
UNIVERSITY OF VIRGINIA PATENT FOUNDATION - Charlottesville VA
THE JOHNS HOPKINS UNIVERSITY - Baltimore MD
THE JOHNS HOPKINS UNIVERSITY - Baltimore MD
International Classification:
A61K 39/00, A61K 35/12, C07K 16/30, A61P 35/00, A61P 35/04, A61P 37/04, C12N 5/0784, C07K 7/08, C07K 14/74, C07K 14/47, G01N 33/566, C07K 7/06, C12N 5/0783
US Classification:
4241851, 530328, 4242771, 5303879, 5303873, 435375, 435325, 530326, 530327, 530405, 530325, 530324, 436501, 435 71
Abstract:
We characterized a total of 175 HLA-DR-associated phosphopeptides using sequential affinity isolation, biochemical enrichment, mass spectrometric sequencing and comparative analysis. Many were derived from source proteins which may have roles in cancer development, growth and metastasis. Most were expressed exclusively by either melanomas or transformed B cells, suggesting the potential to define cell type-specific phosphatome “fingerprints”. We generated HLA-DRβ1*0101-restricted CD4T cells specific for a phospho-MART-1 peptide identified in two melanoma cell lines. These T cells showed specificity for phosphopeptide-pulsed antigen presenting cells as well as for intact melanoma cells. MHC II-restricted phosphopeptides recognizable by human CD4T cells are potential targets for cancer immunotherapy.
Immortal Human Prostate Epithelial Cell Lines And Clones And Their Applications In The Research And Therapy Of Prostate Cancer
Immortal Human Prostate Epithelial Cell Lines And Clones And Their Applications In The Research And Therapy Of Prostate Cancer
US Patent:
6982168, Jan 3, 2006
Filed:
Jan 30, 1997
Appl. No.:
08/913770
Inventors:
Suzanne L. Topalian - Brookeville MD, US
W. Marston Linehan - Rockville MD, US
Robert K. Bright - Portland OR, US
Cathy D. Vocke - Germantown MD, US
W. Marston Linehan - Rockville MD, US
Robert K. Bright - Portland OR, US
Cathy D. Vocke - Germantown MD, US
Assignee:
The United States of America as represented by the Department of Health and Human Services - Washington DC
International Classification:
C12N 15/85
US Classification:
435325, 435366, 435371, 435384, 435385, 435386
Abstract:
The present invention relates to immortalized, malignant, human, adult prostate epithelial cell lines or cell lines derived therefrom useful in the diagnosis and treatment of prostate cancer. More particularly, the present invention relates to cloned, immortalized, malignant, human, adult prostate epithelial cell lines and uses of these cell lines for the diagnosis and treatment of cancer. Furthermore, the present invention provides for the characterization of said cell lines through the analysis of specific chromosomal deletions.